Relapsed multiple myeloma requires specialized expertise that goes beyond general oncology pathways. When disease returns after initial treatment, accessing centers with thorough clinical trial portfolios and novel therapy options becomes critical for optimal outcomes. Key Takeaways Second opinions add value when they unlock clinical trial eligibility, access to CAR-T therapy or bispecific antibodies, or materially different treatment sequencing based on your prior therapy li

Relapsed multiple myeloma demands specialist expertise that goes beyond general oncology. Academic centers with dedicated myeloma programs offer access to clinical trials, advanced cytogenetic interpretation, and treatment-line sequencing strategies that can significantly impact outcomes. Key Takeaways Seek second opinions from dedicated myeloma programs at academic medical centers with specialists who actively participate in clinical trials and interpret cytogenetic markers